TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06138327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT01053702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06068179
Drug: Mycophenolate Mofetil, Oral, 250 Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy
Study: NCT05130970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Study: NCT05821309
Drug: PEG-3350 with electrolytes
Normalized name: PEG-3350 with Electrolytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this study is to determine if a sustained change in the fecal microbiome occurs after prolonged use of an antegrade continence enema bowel flush regimen. Patients' microbiomes will be evaluated via 16s rRNA sequencing. PEG 3350 will be compared to PEG 3350 with electrolytes
Study: NCT05358821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-718-matching oral capsules
Study: NCT05378061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study: NCT06433908
Drug: Salbutamol HFA-152a
Normalized name: HYDROFLUOROCARBON 152A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg (ex-valve), given at 20-second intervals.
Study: NCT06126783
Drug: IBI311
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
Study: NCT05257902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1T bid/day
Study: NCT05095168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05570409
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: initially 1mg/kg in a step-down regime for 6 months
Study: NCT05570409
Drug: Mycophenolate Mofetil Placebo
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF matching Placebo
Study: NCT05570409
Drug: Prednisolone Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone matching placebo
Study: NCT05578482
Drug: Elocon 0.1 % Topical Cream
Normalized name: Elocon 0.1 % Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups are treated with elocon for five days.
Study: NCT05109702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle solution.
Study: NCT05394103
Drug: Q901
Normalized name: Quinelorane
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter
Study: NCT05099237
Drug: Isansys Patient Status Engine
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in cohort 3 will also be asked to wear Isansys monitoring devices whilst they are in hospital. They will begin to wear the monitors prior to CAR T-cell therapy and continue for 28 days post infusion. Participants will be asked to wear an Isansys LifeTouch, Isansys LifeTemp and Nonin Model 3150 WristOx™ Pulse Oximeter during their inpatient stay only, up to a maximum of 28 days.
Study: NCT04771676
Drug: Oncorine (H101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A modified human recombinant type 5 adenovirus with genetic modifications.
Study: NCT06524596
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group received 0.02 mg/kg normal saline intravenously over 5 minutes, 30 minutes before anaesthesia induction
Study: NCT06524596
Drug: propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthesia was induced with 2 mg/kg propofol and 0.6 μg/kg remifentanil and maintained with a target-controlled infusion (TCI) of propofol and remifentanil, using the Marsh and Minto models, respectively.
Study: NCT04984512
Drug: Mitizodone Phosphate tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitizodone Phosphate tablets will be administered with food.
Study: NCT04984512
Drug: Placebo-matching tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered with food.
Study: NCT06206902
Drug: After preconditioning with chemotherapy, F01 will be evaluated.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
Study: NCT05035095
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
Study: NCT05279716
Drug: Eybelis ophthalmic solution 0.002%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic eye drop
Study: NCT05660213
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
Study: NCT05448391
Drug: RIST4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Study: NCT06507488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a Daphnetin Capsule simulants
Study: NCT05507645
Drug: standard medical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet or anticoagulant treatment at the discretion of local investigators.
Study: NCT06386211
Drug: MAGNE-B6 Oral Solution
Normalized name: vitamin B6 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution.
Study: NCT06386211
Drug: MAGNE-B6 New Formulation Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation tablet.
Study: NCT04890106
Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the second arm will receive one drop of the reference drug in both the eyes every evening at approximately 10:00 pm ± 2 hours for 42 days.
Study: NCT05845307
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT02571608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
Study: NCT05446623
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The one in the OA group will be given a bolus of Sufentanil before and during the surgery.
Study: NCT05595772
Drug: Drug: Growth Factors (CGF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of biological membrane of Concentrated growth factor (CGF) over bone grafting and implant
Study: NCT05595772
Drug: Drug: Growth Factors (PRGF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of biological membrane of Plasma rich in growth factors combined with Xenogeneic bone grafting material around immediate implant
Study: NCT06351891
Drug: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
Study: NCT05842681
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single daily oral dose of Azithromycin tablet 500 mg for five days
Study: NCT04859374
Drug: treatment as usual (TAU) (pharmacological)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any pharmacological therapy used for managing chronic pain or chronic migraine
Study: NCT06648772
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream
Study: NCT05795153
Drug: LOU064
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 (Open-Label) taken orally for 12 weeks
Study: NCT04599465
Drug: ELX/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (FDC) tablets for oral administration.
Study: NCT05464368
Drug: [18F]RO-948
Approvals — FDA: no, EMA: no, PMDA: no
Description: Johns Hopkins University has conducted the first in human study in collaboration with Roche for 18F-RO948and found that 18F-RO948isa promising radioligand for imaging tau pathology in AD, showing excellent brain uptake and displaying little off-target binding(22, 17, 34).The injected activity for18F-RO948will be as low as practicable, while still allowing accurate quantification of the PET images.The injected dose of 370MBq(10mCi)has been selected based on the radiation dose estimates for18F-RO948gathered in human subjects provided by Michael Stabin, Ph.D., and in accordance with the principle that radiation doses should be as low as reasonably achievable.~This radiotracer will be manufactured on site in the Mallinckrodt Institute of Radiology Cyclotron Facility, a certified Nuclear Pharmacy.
Study: NCT04771143
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT04771143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo for oral administration
Study: NCT04799353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC)
Study: NCT04799353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT05293626
Drug: NR082 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 1.5E9 vg, 0.05 mL eye/dose.~Dose Escalation:~If drug-related dose-limiting toxicity (DLT) events are observed in ≤ 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be escalated to 4.5E9 vg, 0.05 mL eye/dose (high dose) after approval by SRC.~Dose De-escalation： If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects using the starting dose within 6 weeks after the dosing of NR082, the dose can be de-escalated to 0.5E9 vg, 0.05 mL eye/dose (low dose) after approval by SRC.~If drug-related dose-limiting toxicity (DLT) events are observed in \> 2 of the 6 evaluable subjects within 6 weeks after the dosing of NR082 at the high dose, the dose can be de-escalated to 3.0E9 vg, 0.05 mL eye/dose (intermediate dose) after the approval by SRC.
Study: NCT06271928
Drug: Yijing Keli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once enrolled, participants will be administrated Yijing Keli
Study: NCT05096494
Drug: SP-103
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-103 topical system is worn daily for 12 hours per day for 28 days
Study: NCT05096494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical system is worn daily for 12 hours per day, for 28 days
Study: NCT05397639
Drug: Masupirdine 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Once Daily
Study: NCT05397639
Drug: Masupirdine 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Once Daily
Study: NCT05397639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet, Once Daily
Study: NCT05976932
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
Study: NCT05875402
Drug: Chimeric antigen receptor T cell preparation targeting GCC
Normalized name: Bos taurus red blood cell preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor T cell preparation targeting GCC
Study: NCT05705427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women in the placebo arm will receive a placebo pill daily beginning in the 3rd trimester of pregnancy and continuing through 1 month postpartum.
Study: NCT06043908
Drug: artificial tear eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group and control group were treated with artificial tear eyedrops four times a day.
Study: NCT06583369
Drug: Liangxue ointment（Traditional Chinese Ointment）
Approvals — FDA: no, EMA: no, PMDA: no
Description: The main ingredients of Liangxue Ointment include: Lithospermum sibiricum, Sanguisorba Sanguis, Rehmannia glutinosa, Gardenia, rhubarb, skullcap, borneol, dragon's blood, olibanum and myrrh.~Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Study: NCT06583369
Drug: Urea cream
Normalized name: Amino Acid-Urea Cream
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply 2 times a day, 14 days is a course of treatment, and the treatment is 2 courses.
Study: NCT04622813
Drug: nefopam, ketoprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
Study: NCT04622813
Drug: saline infusion, ketoprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery
Study: NCT05512013
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen taken orally 2 hours prior to exercise
Study: NCT05512013
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celebrex taken orally 2 hours prior to exercise
Study: NCT05512013
Drug: Flurbiprofen 100 mg
Normalized name: flurbiprofen 100 MG
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen taken orally 2 hours prior to exercise
Study: NCT05512013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert placebo taken orally 2 hours prior to exercise
Study: NCT06195189
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed +platinum
Study: NCT05271331
Drug: Wound infiltration with local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded injection of local anestetic (ropivacaine 0.35%, 40ml) in the skin, subcutaneous tissue and muscles at the site of surgical incision.
Study: NCT05036967
Drug: HF medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation patterns of patients with Heart Failure (HF) in an outpatient setting from Colombia.
Study: NCT05441488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment per os
Study: NCT04620746
Drug: Penicillin Major Determinant (PrePen) Skin Testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin testing followed by oral challenge with amoxicillin 250 mg single dose
Study: NCT04620746
Drug: Direct Oral challenge
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral challenge with test dose of amoxicillin 25mg followed by amoxicillin 250mg single dose
Study: NCT06003088
Drug: HSK7653(5mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Study: NCT06003088
Drug: HSK7653(25mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.
Study: NCT05553184
Drug: Nicotinic Acid 50 MG Oral Tablet
Normalized name: Nicotinic acid 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: a total dose of 1050 MG will be ingested. From time 0 to 180 minutes, doses of 150 MG will be repeated every 30 minutes.
Study: NCT05278832
Drug: QLS31905
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS31905 injection
Study: NCT04849715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered orally once daily
Study: NCT05387668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a tablet.
Study: NCT05480475
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 3 (Treatment A2) and on Day 11 (Treatment C2) a single oral dose of 10 mg rosuvastatin will be administered under fasted conditions.
Study: NCT04251819
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo in combination with 0.3 mg of buprenorphine to examine analgesia in acute pain tasks.
Study: NCT06545097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 2 days
Study: NCT02866565
Drug: adipose-derived regenerative cells (ADRCs)
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of the experimental treatment
Study: NCT06185764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for intravenous administration.
Study: NCT04365660
Drug: 18-F FTC 146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
Study: NCT06078904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one pill a day, oral intake
Study: NCT05483504
Drug: F61 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless or slightly yellow liquid, may be slightly opalescent
Study: NCT05483504
Drug: F61 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless or slightly yellow liquid, may be slightly opalescent
Study: NCT06669169
Drug: Jia Shen Tablet Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks
Study: NCT05165992
Drug: Nebulized Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
Study: NCT06487455
Drug: SPH7485
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH7485： Orally, once daily, 50-400mg, 21 days per cycle
Study: NCT00000947
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05107765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill capsules will look same as that of active drug.
Study: NCT05733078
Drug: Oral Rehydration Salt Formulations
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in control group will have a oral rehydration effervescent tablet to take with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks. The control group will then be provided vitamin C (intervention) effervescent tablets to use 1 gram daily with their usual dose of Levothyroxine for 12 weeks, with thyroid function tests assessed at 6 and 12 weeks to see if there is any difference on biochemical testing or clinical scores.
Study: NCT06393348
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04600921
Drug: Placebo 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will receive Placebo 5mg orally daily for 52 weeks.
Study: NCT05371496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo with no active drug once weekly for 12 months
Study: NCT06068855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injections
Study: NCT04994080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD or TIW
Study: NCT04373785
Drug: NG101m
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NG101m capsule continuously twice daily.
Study: NCT04989959
Drug: [18F]PT2385
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]PT2385 infusion
Study: NCT04669158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.
Study: NCT04049630
Drug: LEV 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study: NCT04049630
Drug: LEV 1,5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study: NCT04049630
Drug: LEV 2,5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
Study: NCT04049630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets of placebo will be administrated to the participants.
Study: NCT05414591
Drug: DWP16001 drug A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, Oral, once daily single dose